康缘药业：构建“一体两翼”创新格局，驱动多元化高质量发展

Core Insights - The traditional Chinese medicine industry is experiencing a golden development period driven by national policies and strong market demand [1] - Kangyuan Pharmaceutical aims to integrate modern technology with traditional medicine, focusing on innovative Chinese medicine while also expanding into chemical and biological drugs [1][3] Group 1: Research and Development - Kangyuan Pharmaceutical views R&D as its lifeline, adhering to a "develop one generation, plan one generation" strategy, and has invested continuously for nearly 30 years [2] - The company has established a robust innovation ecosystem supported by national-level platforms, focusing on high-end talent and collaborative research [2] - Kangyuan has achieved significant milestones, including over 600 invention patents and 58 new Chinese medicine drugs, and has received multiple awards for its research capabilities [2] Group 2: Strategic Development - The company employs a "one body, two wings" strategy, focusing on innovative drug development while also engaging in generic drug production [3] - Since entering the chemical drug sector in 2004, Kangyuan has adopted a dual-track model of "independent R&D + collaborative development" [3] - The company has made significant investments in biological drug research, establishing a comprehensive R&D platform and engaging in international collaborations and acquisitions [3] Group 3: Future Outlook - Kangyuan Pharmaceutical plans to continue leveraging scientific innovation as its core engine while promoting the synergy between chemical and biological drugs [4] - The company aims to build a sustainable R&D pipeline and accelerate the commercialization of its research outcomes to achieve diversified and high-quality growth [4]